A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2014
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders; Insomnia
- Focus Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 02 Dec 2008 Results published in The Lancet.
- 10 Nov 2007 Status changed from in progress to completed.
- 10 Jul 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History